Targeted Fat Loss Made Possible: How Adipotide Transforms Obesity Care
A short clinician-training style walkthrough of adipotide (FTPP), covering how Sewell says it works, dosing, kidney monitoring and three illustrative cases.
With Dr. Adam Sewell (M.D.)
Key moments
Tap a moment to play the video from there.
- 0:00Introduction to adipotide FTPPSewell frames the session as training on adipotide, covering mechanism, uses, dosing, risks, alternatives, lab monitoring and three case studies.
- 0:33How adipotide is said to workHe describes a pro-apoptotic peptide that targets the blood supply of white fat, leading to fat cell death and, he says, better insulin sensitivity.
- 1:50Listed clinical applicationsSewell lists obesity, insulin resistance and type 2 diabetes, metabolic syndrome, off label aesthetic use, and pairing with lifestyle changes.
- 2:32Claimed benefitsHe names targeted fat reduction, improved metabolic health, a non-hormonal route and visible changes within weeks.
- 3:08Potential risks and data gapsHe cites kidney effects from preclinical studies, injection site reactions, nausea and fatigue, and says long-term human data is limited.
- 3:39Alternatives to adipotideSewell lists aesthetic procedures, weight loss medications, metformin and lifestyle changes as other options.
- 4:10Dosage and administrationHe gives subcutaneous daily doses per kilogram of body weight, for 2 to 4 weeks, with cycles repeated as needed.
- 4:45Lab testing and monitoringHe outlines baseline metabolic and kidney labs, weekly renal tests during treatment, and repeat labs and body composition afterward.
- 5:35Three clinical case studiesSewell walks through an insulin resistance case, a fatty liver case and an aesthetic abdominal case, each with reported improvements.
- 7:02Conclusion and course promotionHe summarizes adipotide as a distinct approach to fat loss and ends by promoting a free peptide certification course.
What the video says
This is a 7.5 minute training presentation by Dr. Adam Sewell on adipotide, which he also calls FTPP. He describes it as a pro-apoptotic peptide meant to reduce white adipose tissue by disrupting the blood supply to fat. He contrasts it with weight loss approaches that act on appetite or metabolism.
Sewell says adipotide binds receptors on the blood vessels that feed white fat, which leads to programmed death of fat cells and, over time, less fat mass. He also says that shrinking the fat burden improves insulin sensitivity and metabolic markers. The uses he lists are obesity management, insulin resistance and type 2 diabetes, metabolic syndrome, off label aesthetic fat reduction, and as an add-on to diet and exercise. Benefits he names include targeted fat reduction, a non-hormonal mechanism, and visible changes within weeks.
On safety, Sewell says renal toxicity is the main concern, citing transient kidney effects seen in preclinical studies, along with injection site reactions, nausea and fatigue. He says preclinical data is robust but long-term human data is limited. He lists liposuction, cool sculpting, GLP-1 type medications, metformin and lifestyle changes as alternatives.
The practical section gives his dosing and monitoring. He states a subcutaneous dose of 0.5 to 1.0 mg per kilogram daily for obesity management, 0.5 mg per kilogram daily for aesthetic use, and cycles of 2 to 4 weeks. He recommends baseline metabolic and kidney labs, weekly renal function tests during treatment, and repeat labs and body composition checks afterward. He then presents three short cases, an insulin resistance case, a fatty liver case and an aesthetic abdominal case, each reported as improving without significant adverse effects. The video closes with a promotion for a free peptide certification course.
On each compound
Adipotide0:33
Sewell describes adipotide (FTPP) as a pro-apoptotic peptide that disrupts the blood supply to white fat and induces fat cell death. He states doses of 0.5 to 1.0 mg per kilogram daily for 2 to 4 weeks, flags kidney toxicity as the main risk, and reports favorable results in three cases.
See how your DNA reads AdipotideWhat this video doesn’t settle
- The three case studies are brief, unnamed and uncontrolled, with no source given, so they cannot show that adipotide caused the reported changes.
- Sewell cites no clinical trials, and by his own account long-term human data is limited, so the dosing and benefit claims are not backed by data shown in the video.
- He mentions kidney toxicity from preclinical studies but gives no human safety figures, and the video does not address regulatory status or how the peptide is sourced.
Questions this video answers
How does adipotide work according to Dr. Sewell?
Sewell says adipotide binds receptors on the blood vessels that supply white adipose tissue and disrupts that blood supply. He says this causes programmed death of fat cells, which reduces fat mass over time.
What side effects of adipotide does the video mention?
Sewell lists kidney toxicity seen in preclinical studies as the main concern, plus injection site redness, swelling or discomfort, and occasional nausea and fatigue. He says long-term human data is limited and recommends close monitoring.
What dose and schedule does the video describe for adipotide?
Sewell states 0.5 to 1.0 mg per kilogram of body weight daily by subcutaneous injection for obesity management, and 0.5 mg per kilogram daily for aesthetic use. He says treatment typically runs 2 to 4 weeks and may be repeated in cycles.
What lab tests does Dr. Sewell recommend with adipotide?
He recommends a baseline metabolic panel focused on kidney function, a lipid profile, fasting glucose, HbA1c and body composition analysis. During treatment he says to run weekly renal function tests and track weight and waist circumference, then repeat labs afterward.
What case studies does the adipotide video present?
Sewell presents a 50-year-old woman with obesity and insulin resistance, a 45-year-old man with metabolic syndrome and fatty liver, and a 35-year-old woman with abdominal fat. He reports improved measures and no significant adverse effects in each.
Video by Dr. Adam Sewell, M.D. | Medical Entrepreneur on YouTube, embedded as published. The summary is written by PeptidesDNA from the video; every claim in it is the speaker’s. Not affiliated with or endorsed by the creator. Not medical advice.
